CAV1 and gastric neoplasm: Cav-1 reduction in cancerous lesion was more frequent in early (22 of 39, 56.4%) versus advanced (24 of 61, 39.3) tumors while its elevation was more common in advanced (22 of 61, 36.1%) versus early (8 of 39, 20.5%) tumors, further supporting the biphasic alteration of Cav-1 expression during gastric tumor progression (Fig. 2c).